Cepheid (NASDAQ:CPHD) was down 2.4% during trading on Wednesday . The company traded as low as $31.15 and last traded at $31.18, with a volume of 541,081 shares trading hands. The stock had previously closed at $31.95.

A number of equities research analysts recently commented on CPHD shares. Wedbush decreased their target price on shares of Cepheid from $58.00 to $55.00 and set an “outperform” rating for the company in a research report on Monday, March 28th. BTIG Research raised shares of Cepheid from a “neutral” rating to a “buy” rating and set a $42.00 target price for the company in a research report on Friday, April 1st. Atlantic Securities raised shares of Cepheid from a “neutral” rating to an “overweight” rating in a research report on Friday, April 1st. Canaccord Genuity restated a “hold” rating and set a $32.00 price target on shares of Cepheid in a research note on Wednesday, June 29th. Finally, Zacks Investment Research upgraded shares of Cepheid from a “hold” rating to a “buy” rating and set a $32.00 price target on the stock in a research note on Tuesday, June 28th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and thirteen have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $41.58.

The firm’s market capitalization is $2.30 billion. The stock has a 50 day moving average price of $28.88 and a 200-day moving average price of $31.15.

Cepheid (NASDAQ:CPHD) last announced its quarterly earnings data on Thursday, April 28th. The company reported $0.08 EPS for the quarter, topping the Zacks’ consensus estimate of $0.01 by $0.07. During the same quarter in the previous year, the business posted $0.17 earnings per share. The business had revenue of $144.80 million for the quarter, compared to analyst estimates of $140.35 million. The company’s revenue was up 9.2% compared to the same quarter last year. On average, analysts expect that Cepheid will post $0.25 earnings per share for the current year.

In other news, CEO John L. Bishop sold 110,000 shares of Cepheid stock in a transaction dated Monday, April 25th. The stock was sold at an average price of $35.50, for a total transaction of $3,905,000.00. Following the completion of the sale, the chief executive officer now directly owns 194,449 shares in the company, valued at approximately $6,902,939.50. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Scott A. Campbell sold 2,058 shares of Cepheid stock in a transaction dated Tuesday, May 3rd. The shares were sold at an average price of $27.90, for a total value of $57,418.20. Following the sale, the vice president now owns 13,761 shares of the company’s stock, valued at $383,931.90. The disclosure for this sale can be found here.

Other large investors have recently made changes to their positions in the company. Columbia Wanger Asset Management LLC raised its stake in shares of Cepheid by 5.2% in the fourth quarter. Columbia Wanger Asset Management LLC now owns 5,360,677 shares of the company’s stock valued at $195,826,000 after buying an additional 265,403 shares in the last quarter. Stephens Investment Management Group LLC raised its stake in shares of Cepheid by 17.0% in the fourth quarter. Stephens Investment Management Group LLC now owns 964,912 shares of the company’s stock valued at $35,248,000 after buying an additional 140,090 shares in the last quarter. Kornitzer Capital Management Inc. KS raised its stake in shares of Cepheid by 111.4% in the fourth quarter. Kornitzer Capital Management Inc. KS now owns 658,182 shares of the company’s stock valued at $24,043,000 after buying an additional 346,809 shares in the last quarter. American Capital Management Inc. raised its stake in shares of Cepheid by 48.2% in the fourth quarter. American Capital Management Inc. now owns 529,840 shares of the company’s stock valued at $19,355,000 after buying an additional 172,225 shares in the last quarter. Finally, New York State Common Retirement Fund raised its stake in shares of Cepheid by 0.7% in the fourth quarter. New York State Common Retirement Fund now owns 284,504 shares of the company’s stock valued at $10,393,000 after buying an additional 2,000 shares in the last quarter.

Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company’s systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.